Induction therapy and outcome of proliferative lupus nephritis in the top end of Northern Australia – a single centre study retrospective study

Table 6 Incidence of infection related hospitalisations over the follow-up period in patients treated with mycophenolate

	Total	Non-Indigenous	Indigenous Australians	IRR^b (95% CI)	P-value
Total number	20	5	15
Time at risk (ptyr^a)	87.55	12.48	75.07
Infection related admissions	46	2^c	44
Incidence rate (per ptyr)	0.53	0.16	0.59	3.66 (0.89—15.09)	0.073
Infection related ICU admissions	8	1	7
Incidence rate (per ptyr)	0.09	0.08	0.09	1.16 (0.14 – 9.45)	0.599

^aPtyr Patient-year, ^bIRR Incidence rate ratio, ^cOne patient had VZV PCR positive shingles, another patient had infective colitis while in Singapore and was admitted to ICU with septic shock

ISSN: 1471-2369